Aspergillus GM LFA

Over 30 million people are at risk of invasive aspergillosis each year because of corticosteroid use or other therapies, and over 300.000 patients develop it annually.

The disease is common in high risk patients with:
• Hematological malignancies
• Chemotherapy-induced neutropenia
• Allogeneic HSCT (stem cell transplant)
• Solid organ transplant (primarily lung)

Key Advantages of the Aspergillus GM LFA:
• 30 Minute test time
• Simplified procedure
• High sensitivity and specificity
• Serum & BAL specimens
• Test more frequently/Eliminate batch testing

AF2003 Brochure

Please contact us if you need a specific product, we are meeting many customers’ unique requests.

Go to webshop

×

Reminder transition to our new ERP system (SAP S4.HANA) – first week of January 2026.

Important information and preparations:
• Orders for delivery this year can still be placed until 17 December 2025.
• Online orders placed after 17 December can be placed as normal, but delivered after January 9th.
• No shipments will be sent between 19 December 2025 and 8 January 2026.
• Normal shipments are expected to resume from 9 January 2026.

For urgent matters or questions, please email: sales.nl@analytichem.com

Find out more
0
Your Cart
Your cart is empty
Calculate Shipping